Idiopathic intracranial hypertension without papilledema (IIHWOP) in chronic refractory headache by Favoni, Valentina et al.
ORIGINAL RESEARCH
published: 26 June 2018
doi: 10.3389/fneur.2018.00503
Frontiers in Neurology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 503
Edited by:
Vincenzo Guidetti,
Sapienza Università di Roma, Italy
Reviewed by:
Marcelo M. Valença,
Universidade Federal de Pernambuco,
Brazil
Cherubino Di Lorenzo,
Fondazione Don Carlo Gnocchi Onlus
(IRCCS), Italy
*Correspondence:
Sabina Cevoli
sabina.cevoli@unibo.it
Specialty section:
This article was submitted to
Headache Medicine and Facial Pain,
a section of the journal
Frontiers in Neurology
Received: 24 March 2018
Accepted: 08 June 2018
Published: 26 June 2018
Citation:
Favoni V, Pierangeli G, Toni F, Cirillo L,
La Morgia C, Abu-Rumeileh S,
Messia M, Agati R, Cortelli P and
Cevoli S (2018) Idiopathic Intracranial
Hypertension Without Papilledema
(IIHWOP) in Chronic Refractory
Headache. Front. Neurol. 9:503.
doi: 10.3389/fneur.2018.00503
Idiopathic Intracranial Hypertension
Without Papilledema (IIHWOP) in
Chronic Refractory Headache
Valentina Favoni 1,2, Giulia Pierangeli 1,2, Francesco Toni 3, Luigi Cirillo 3,
Chiara La Morgia 1,2, Samir Abu-Rumeileh 1,2, Monica Messia 3, Raffaele Agati 3,
Pietro Cortelli 1,2 and Sabina Cevoli 1*
1Unità Operativa Complessa Clinica Neurologica, IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy,
2Department of Biomedical and NeuroMotor Sciences, Alma Mater Studiorum–University of Bologna, Bologna, Italy,
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Background: To determine the prevalence of Idiopathic intracranial hypertension without
papilledema (IIHWOP) testing revised diagnostic criteria by Friedman in refractory chronic
headache (CH) patients.
Methods: This is a prospective observational study. Each patient underwent
ophthalmologic evaluation and Optical Coherence Tomography; brain magnetic
resonance venography (MRV) and a lumbar puncture (LP) with opening pressure (OP)
measurement. CSF withdrawal was performed in patients with CSF OP > 200 mmH20.
IIHWOP was defined according Friedman’s diagnostic criteria. Effect of CSF withdrawal
was evaluated clinically in a 6-month follow-up and with a MRV study at 1 month.
Results: Forty-five consecutive patients were enrolled. Five were excluded due to
protocol violations. Analyses were conducted in 40 patients (32 F, 8M; mean age 49.4 ±
10.8). None had papilledema. Nine patients (22.5%) had OP greater than 200 mmH2O,
two of them above 250 mmH2O. Two (5%) had neuroimaging findings suggestive of
elevated intracranial pressure. One of them (2.5%) met the newly proposed diagnostic
criteria by Friedman for IIHWOP. After CSF withdrawal seven (77.8%) of the nine patients
improved. No changes in neuroimaging findings were found.
Conclusions: We found a low prevalence (2.5%) of IIHWOP in refractory CH patients
according to current diagnostic criteria. In agreement with Friedman’s criteria, our results
confirm that a diagnosis of IIHWOP should be based on CSF OP and the combination of
neuroradiological findings. However, where to set the CSF OP upper limit in IIHWOP
needs further field testing. Although IIHWOP is a rare clinical condition, it should be
considered and treated in refractory CH patients.
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INTRODUCTION
Chronic headache (CH) is a challenging clinical entity because management is complex and often
unsatisfactory. A diagnosis of idiopathic intracranial hypertension without papilledema (IIHWOP)
should be considered in patients with CH refractory to preventive therapy. Headache attributed
to IIHWOP often mimics chronic migraine or chronic tension-type headache and the distinction
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from primary headaches can be clinically difficult. Lumbar
puncture (LP) is mandatory to confirm diagnosis, but
controversies exist regarding the CSF opening pressure
(OP) cut-off value for the diagnosis of intracranial hypertension.
The early accepted upper limit of normal CSF pressure was 200
mmH2O (1). Based on a long history of evidence (2, 3), recently,
revised diagnostic criteria for pseudotumor cerebri syndrome
by Friedman set the upper limit to 250 mmH2O and recognized
the importance of MRI (4). According to these criteria, in the
absence of papilledema or sixth nerve palsy, the diagnosis of
IIHWOP can be suggested by the combination of elevated OP
and the presence of at least three of the following neuroimaging
findings: empty sella, distention of the perioptic subarachnoid
space with or without a tortuous optic nerve, flattening of the
posterior sclerae and transverse venous sinus stenosis (Table 1).
Undoubtedly, the diagnosis of IIHWOP is mandatory to improve
patient management. The aim of this study was to verify the
prevalence of IIHWOP in chronic headache patients resistant to
prophylactic therapies and to test revised diagnostic criteria by
Friedman.
MATERIALS AND METHODS
Outcome Measures
The primary endpoint of the study was to analyze the prevalence
of IIHWOP in a series of consecutive refractory chronic headache
patients.
The secondary endpoints were to test the revised diagnostic
criteria by Friedman to detect IIHWOP and to verify the effect of
CSF withdrawal on headache frequency and intensity.
Standard Protocol Approvals and Patient
Consents
The study was conducted in agreement with principles of good
clinical practice and the study protocol was approved by the Local
Ethics Committee of the local health service of Bologna, Italy (n.
12017/CE). All patients gave their written informed consent to
study participation.
Participants
Patients with refractory chronic migraine (CM) and Chronic
Tension-type Headache (CTTH) with or without medication
overuse referred to the tertiary Headache Centre of IRCCS
Institute of Neurological Sciences of Bologna, Italy, were
consecutively recruited from September 2013 to February
2016. Diagnosis of CM, CTTH and medication overuse were
established according to the International Classification of
Headache Disorders-3 beta version criteria (5). Refractoriness
was defined as the failure of at least 3 trials of preventive
therapies at adequate doses and at least one detoxification
attempt in case of medication overuse. Inadequate response was
defined as absence of reduction of migraine attack frequency
or days by at least 50% after at least 3 months of therapy at a
stable dose considered appropriate for migraine or tension type
prevention according to accepted guidelines (6, 7). Exclusion
criteria included the presence of papilledema on a routine
TABLE 1 | Diagnostic criteria for pseudotumor cerebri syndrome (4).
1. Required for diagnosis of pseudotumor cerebri syndromea
A. Papilloedema
B. Normal neurologic examination except for cranial nerve abnormalities
C. Neuroimaging: Normal brain parenchyma without evidence of hydrocephalus,
mass, or structural lesion and no abnormal meningeal enhancement on MRI,
with and without gadolinium, for typical patients (female and obese), and MRI,
with and without gadolinium, and magnetic resonance venography for others;
if MRI is unavailable or contraindicated, contrast-enhanced CT may be used
D. Normal CSF composition
E. Elevated lumbar puncture opening pressure (>250mm CSF in adults and
>280mm CSF in children [250mm CSF if the child is not sedated and not
obese]) in a properly performed lumbar puncture
2. Diagnosis of pseudotumor cerebri syndrome without papilloedema
i. In the absence of papilloedema, a diagnosis of pseudotumor cerebri syndrome
can be made if B–E from above are satisfied, and in addition the patient has a
unilateral or bilateral abducens nerve palsy.
ii. In the absence of papilloedema or sixth nerve palsy, a diagnosis of pseudotumor
cerebri syndrome can be suggested but not made if B–E from above are
satisfied, and in addition at least three of the following neuroimaging criteria
are satisfied:
iii. Empty sella
iv. Flattening of the posterior aspect of the globe
v. Distention of the perioptic subarachnoid space with or without a tortuous optic
nerve
vi. Transverse venous sinus stenosis
aA diagnosis of pseudotumor cerebri syndrome is definite if the patient fulfills criteria
A–E. The diagnosis is considered probable if criteria A–D are met but the measured CSF
pressure is lower than specified for a definite diagnosis.
fundoscopic examination, age <18 years, pregnancy and breast-
feeding, secondary headaches, as well as serious ongoing physical
or psychiatric illness.
Study Protocol
Each participant underwent: (1) a complete neurological
and physical examination including height and weight
measurements; (2) ophthalmologic evaluation with funduscopic
examination and Optical Coherence Tomography (OCT) to rule
out the presence of papilledema; (3) brain magnetic resonance
imaging (MRI) including magnetic resonance venography
(MRV) to detect neuroimaging features highly suggestive
of idiopathic intracranial hypertension including transverse
sinus stenosis, empty sella, flattening of the posterior aspect
of the globe and distension of the perioptic subarachnoid
space with or without a tortuous optic nerve; (4) an LP to
measure CSF OP, which is the gold standard for the diagnosis
of idiopathic intracranial hypertension. Prior to diagnostic
procedures, we performed face-to-face structured interviews
to gather detailed information about the clinical features of
headache and associated symptoms including age at onset, days
of headache per month, side and intensity of pain, years of
chronic headache; presence, duration, and type of medication
overuse; and potential related comordidities such as sleep apnea
were ruled out. Headache diary data referring to 30 days before
LP were collected as baseline evaluation.
Frontiers in Neurology | www.frontiersin.org 2 June 2018 | Volume 9 | Article 503
Favoni et al. IIHWOP in Chronic Refractory Headache
Optical Coherence Tomography (OCT)
Subjects underwent average and single sector (temporal, superior,
nasal and inferior) RNFL thickness measurements by OCT
(StratusOCT, software version 4.0.1; Carl Zeiss Meditec Inc,
Dublin, CA, USA). We used the RNFL thickness 3.4 acquisition
protocol, as previously described (8). Patients were compared
with age- and sex-matched controls. For both groups we used a
randomly selected eye for statistical analysis.
MR Imaging and MR Venography
Each patient underwent an MRI morphological study of the
brain, carried out with a 3T MR system (Signa 3T GE) with
a standard head coil. All the examinations included T1 and
T2 weighted sequences and MRV studies. MRV studies were
executed with 2D time-of-flight sequence acquired in the coronal
plane and with a 3D contrast-enhanced ultrafast gradient-
echo angiographic sequence with elliptic centric ordering of k-
space collection (Time Resolved Imaging of Contrast Kinetics-
TRICKS). The sequence was acquired in the sagittal plane
with covering the whole head. Venous phase correct time
delay was calculated administering a small 2ml test bolus
of gadolinium chelates followed by 10ml bolus of normal
saline. The angiographic sequence was then acquired after
the injection of a 30ml bolus of gadolinium chelate contrast
agent at a rate of 2 ml/s followed by 30ml saline flush
at 2 ml/s.
Image Processing and Review
Source images from contrast-enhanced MRV (CE-MRV) of
each patient were reviewed on a PACS viewing workstation
by two neuroradiologists (F.T. and L.C.) who were blinded
to the patient’s clinical features. In addition to the sagittal
source images it was also possible to review reformatted images
of the volume using 1–2mm thick section in the coronal
and axial plane and 3D maximum intensity projection (MIP)
reconstructions. Transverse sinus stenosis, empty sella, flattening
of the posterior aspect of the globe and distension of the
perioptic subarachnoid space with or without a tortuous optic
nerve were defined as present or absent. The presence of
at least three of four neuroimaging findings were needed to
satisfied Friedman’s criteria (4). Disagreements were resolved by
consensus.
Lumbar Puncture
All LPs were performed as previously described, using a 20
gauge spinal needle and with the patient lying in the lateral
decubitus position (9). CSF OP was measured by a standard
spinal manometer calibrated in mmHg connected to the spinal
needle via a three-way stopcock. All pressure values were
multiplied by 13.56 (the Hg specific weight) for the conversion
in mm H2O. We used the OP value of 250 mmH2O to define
IIHWOP according to Friedman’s criteria (4). According to
previous findings that suggest that CSF withdrawal may result
in a sustained remission of chronic migraine, we performed
CSF withdrawal in patients with OP values above 200 mmH2O:
intracranial pressure measurements were repeated every 2mL of
extracted CSF, up to about 100 mmH2O (9). In patients who
showed an OP ≤ 200 mm H2O, the procedure was stopped after
a 6mL CSF withdrawal for routine analysis.
Follow-Up
A follow-up visit at 1 month was planned for all patients. Effect
of CSF withdrawal was evaluated in patients with an OP > 200
mmH2O at 1, 3 and 6 months after LP. Moreover, the MRI study
including MRV was repeated 1 month after CSF withdrawal to
evaluate changes in neuroimaging findings. Patients recorded all
headache attacks and drugs taken for headache during the whole
study period on a clinical diary.
Statistics
All data were analyzed using the SPSS software package
(version 21- IBM Analytics). T-test or Mann-Whitney test, as
appropriate, was used to compare continuous variables, while
Chi-square test was adopted for categorical variables. Results
were expressed by mean ± standard deviation, median with
interquartile range (IQR) or percentage. The Spearman bivariate
test was used to detect the strength of correlation between
selected variables. Values of p < 0.05 were considered statistically
significant. A Bonferroni correction was applied for multiple
comparisons.
RESULTS
Forty-five patients were enrolled. Five patients were excluded due
to protocol violations (one patient withdrew consent, two refused
to undergo LP, one refused to undergo brain MRV and one
refused to undergo both LP andMRV). Analyses were conducted
in 40 patients (32 F, 8M; mean age 49.4± 10.8; mean BMI 26.7±
6.4).
The diagnosis of headache was chronic migraine in 39 patients
(97.5%) and chronic tension-type headache with concomitant
episodic migraine in 1 patient. Mean chronification duration
was 11.6 ± 9.9 years (range 1–32 years). At baseline mean
headache frequency was 26.5 ± 6.5 days/month. Overall, 37
patients (92.5%) weremedication overusers. Themost commonly
overused agents were triptans (N = 20; 54%) and non-steroidal
anti-inflammatory drugs (n = 14; 37.8%). Fifteen patients
(37.5%) overused two or more different compounds at a time
(Table 2). Three patients complained of symptoms suggesting
IIWHOP, such as tinnitus.
Neurological Examination
Neurological examination was unremarkable in all patients.
None of them had unilateral or bilateral abducens nerve palsy.
Ophthalmological Examination and OCT
None of the patients had papilledema. All the patients underwent
OCT. Four patients were excluded due to poor quality of OCT
scan images. Thirty-six patients (29 F, 7M; mean age 49.3 ± 10.8
years; range 22–67 years) were compared to 43 sex- and age-
matched controls (32 F, 11M; mean age 49.6 ± 12.1 years; range
23–68 years). The RNFL average thickness was within normal
range in both groups and did not significantly differ between
patients and controls (99.1 ± 8.9µm in migraine patients vs
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TABLE 2 | Demographic and baseline clinical characteristics of the study sample.
TOTAL
Sample N (%) 40
Age mean ± SD 49.4±10.8
SEX
Males N (%) 8 (20.0)
Females N (%) 32 (80.0)
MARITAL STATUS
Single N (%) 7 (17.5)
Married N (%) 27 (62.5)
Separated/Divorced N (%) 5 (12.5)
Widower N (%) 1 (2.5)
Years of Education mean ± SD 11.3 ± 3.5
EMPLOYMENT
Unemployed N (%) 3 (7.5)
Student N (%) 1 (2.5)
Employee N (%) 21 (52.5)
Housewife N (%) 4 (10.0)
Retired N (%) 6 (15.0)
Self-employed N (%) 5 (12.5)
BMI
<20 N (%) 2 (5.0)
20–25 N (%) 16 (40.0)
25–30 N (%) 14 (35.0)
>30 N (%) 8 (20.0)
HEADACHE
Age at Headache Onset mean ± SD 16.6 ± 8.3
Age of Headache Chronification mean ± SD 37.8 ± 11.3
Duration of chronification in years mean ± SD 11.6 ± 9.9
Headache frequency (days/month) mean ± SD 28.1 ± 4.1
Frequency of medication intake (days/month) mean ± SD 26.5 ± 6.9
OVERUSED DRUGS
Triptans N (%) 20 (50.0)
simple analgesics and/or NSAIDs N (%) 21 (52.4)
Combination analgesics N (%) 15 (37.5)
99.5 ± 13.0µm in controls, p = 0.8). Moreover, there was no
significant difference in the RNFL thickness in any of the optic
nerve quadrants analyzed.
LP
Two of forty patients (5%) had an OP above 250 mmH2O.
Other seven (17.5%) had an OP between 200 and 250 mmH2O.
All patients displayed normal CSF composition. We compared
patients with OP < 200 mmH2O (Group 1) with those
with OP > 200 mmH2O (Group 2). No statistical significant
differences were found between group 1 and 2 regarding age,
sex, years of education, duration of chronification (Table 3).
Regarding BMI a statistical difference (p = 0.015) was found
before Bonferroni correction. Two of the three patients with
tinnitus have OP between 200 and 250 mmH2O.
Neuroimaging Criteria
All patients had normal brain parenchyma. Two of them (5%)
had at least three of the four neuroimaging findings suggestive of
elevated intracranial pressure as proposed by Friedman’s criteria
(Table 4). One of them had all the findings (Figure 1). The
other had evidence of transverse sinus stenosis, empty sella, and
distension of the perioptic subarachnoid space.
Prevalence of IIHWOP
One patient (2.5%) satisfied the diagnostic criteria for IIHWOP
proposed by Friedman (Table 5). She had both OP > 250
mmH2O and all of the four neuroimaging features.
The other patient who had at least three of the four
neuroimaging findings had OP > 200 mmH2O, but lower than
250 mmH2O. The other patient with OP > 250 mmH2O had
none of neuroimaging criteria.
Follow-Up
At 1 month, considering the whole sample, 15 patients (37.5%)
improved after LP, 23 (57.5%) had no benefit and 2 (5%) were
lost at follow-up. Out of those that ameliorated, 8 had OP <200
mmH2O, 5 had OP between 200 and 250 mmH2O, and 2 had
OP > 250 mmH2O. Among them, there were no statistically
significant differences regarding age (p = 0.694), sex (0.605),
BMI (p = 0.072), years of education (p=0.955) and duration
of chronification (p = 0.897), even after Bonferroni correction
between the subgroups of patients with OP < 200 mmH20
(n = 8) or those with p> 200 mmH20 (n = 7). Considering
the 9 patients with OP >200 mmH2O, seven (77.8%) improved
after withdrawal (Table 4). The two patients with OP > 250
mmH2O achieved an improvement of headache intensity and
one of them a reduced frequency of medication intake, but no
changes in the frequency of attacks. Among the five patients
with OP ranging from 200 to 250 mmH2O, four experienced a
return to episodicmigraine and one decreased headache intensity
and acute medications intake; one of them achieved also the
recovery of tinnitus. A trial with acetazolamide was taken in
account in patients with no contraindications to the use of this
drug, and compliant to the treatment. All the 9 patients with
OP>200 mmH2O repeated MRV 1 month after CSF withdrawal.
No changes of neuroimaging findings were found.
At 3 months one of the two patients with OP > 250 mmH2O
relapsed, none of them was treated with acetazolamide due to
contraindications, and one was lost at follow-up. Among those
with OP between 200 and 250 mmH2O, three patients still
presented with an episodic migraine (two of them were treated
with acetazolamide) and one patient was lost because she got
pregnant. At 6 month of follow-up one relapsed to CM and two
patients continued to have an episodic migraine (Table 4).
DISCUSSION
In our series, we found a low prevalence of IIHWOP in
refractory CH patients. Only one of forty patients (2.5%) who
had OP greater than 250 mmH2O and the neuroimaging
finding suggestive of elevated intracranial pressure met the newly
proposed diagnostic criteria by Friedman (4). Indeed, according
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TABLE 3 | Comparisons of features of patients with OP<200 mmH2O and patients with OP > 200 mmH2O (Group 1 and Group 2).
Mean value ± SD Median (IQR) % OP < 200 mmH2O (N = 31) OP > 200 mmH2O (N = 9) P-values Bonferroni adjusted p-values
Age (years) 49±12 50±8 0.858 n.s.*
Female (%) 77.4 88.9 0.776 n.s*
BMI 25±5 24 (22–27) 32±7 34 (25–38) 0.015 n.s*
Opening pressure 159±28 163 (143–184) 245±51 224 (211–258) <0.001 Significant*
Years of education 11±3 13 (8–13) 11±4 13 (8–13) 0.757 n.s.*
Duration of chronification in years 10±9 10 (3–15) 16±13 10 (5–28) 0.407 n.s.*
n.s. not significant.
*values of p <0.008 were considered statistically significant.
to these criteria, CSF OP alone is not suitable for making
a diagnosis and imaging has become an integral part of our
diagnostic armamentarium for the diagnosis of IIHWOP. The
upper limit of normal intracranial pressure is still debated (4, 10,
11). First of all, increased CSF OP may be due to several factors,
including pain, anxiety, sedation, anesthesia, flexing of the neck
and Valsalva maneuvers. In order to minimize false positive
values a standardized procedure is essential with patients placed
in a lateral decubitus position, as relaxed as possible, with legs
stretched before pressuremeasurements. Moreover, CSF pressure
monitoring demonstrated that intracranial pressure fluctuates
during the day, ranging from normal to pathologic values. This
implies that a single-spot opening measurement of CSF OP may
fail to identify this condition, if the cut-off value is set at 250
mmH2O (12). However, although CSF pressure monitoring has
a high accuracy in recognizing elevated intracranial pressure, it
is an invasive procedure that is not practicable in routine use
(12, 13). Moreover, the risk to overestimate the syndrome should
be taken into account, if the cut-off value is set at 200 mmH2O.
Asymptomatic OP greater than 200 mmH2O was found in
11% of neurological patients, probably similar to the general
population (10). Previous studies in headache patients reported
OP > 250 mmH2O ranging from 5 to 55.5% and OP > 200
mmH2O ranging from 10 to 100% (Table 6) (9, 12–17). These
heterogeneous results may be mainly due to different methods
and patient selection. Moreover, limited data are available in CH
patients, especially those refractory to treatments. In our series,
we found OP > 250 mmH2O and OP > 200 mmH2O in 5
and 22.5% respectively. Our results are significantly lower than
those recently reported in a series of 44 unresponsive chronic
migraine patients, where OP > 250 mmH2O and OP > 200
mmH2O were found in 43.2 and 86.4% respectively (9). In
this latter study MRV was used for selecting patients with
transverse sinus stenosis, however the difference in outcome
cannot be easily explained by different patient selection criteria
(18).
To our knowledge, our study is the first one that focused
on the combination of neuroradiological findings and OP in
refractory CH patients to test IIHWOP criteria. Between the two
patients (5%) that satisfied neuroimaging criteria, both have OP
higher than 200mmH2O, but only one higher than 250mmH2O.
On the contrary, considering CSF OP > 250 mmH2O alone,
the prevalence of IIHWOP may rise to 5%. However, between
the two patients with OP greater than 250 mmH2O, one failed
to meet diagnostic criteria due to the absence of neuroimaging
findings. Despite the effort to use a standardized procedure, we
cannot exclude that the OP found in this patient was a false
positive value. Consequently, using CSF OP alone, the risk is
to overestimate a diagnosis. These findings confirm the need to
combine OP and neuradiological criteria to make the diagnosis.
Moreover, we confirm that neuroimaging features persist after
CSF withdrawal (19). This is in contrast with recent evidence
showing the reversibility of stenosis after intracranial pressure
normalization (20, 21). The difference in outcome can be related
to different timing ofMRV after withdrawal and to the hypothesis
that transverse sinus stenosis is only one of the contributing
factors involved in IIHWOP (19).
Our results confirm that CSF withdrawal may have clinical
effects on headache in CH patients, with long-term effect
(9, 12, 16, 22). A proportion of 77.8% of our refractory
patients with OP > 200 mmH2O reported improvement of
headache frequency and/or intensity until up to 6 months after
withdrawal. Only partial improvement was reported by patients
with OP > 250 mmH2O, but the number is too small to
make certain assumptions. Moreover, a placebo effect could not
be excluded, considering that 25.8% of patients with OP<200
mmH2O improved after LP. However, we are pretty certain that
clinical features did not differ between patients with OP>200
mmH2O and patients with OP < 200 mmH2O. Interestingly, it
appears that there was a trend toward statistical significance with
the OP and BMI. Patients with higher BMI are trending toward
higher OP. Based on a previous meta-analysis of observational
studies that suggests an association betweenmigraine and obesity
(23), we suppose that refractory headache may be related with
BMI andOP.Moreover, we can argue that patients withOP> 200
mmH2O may potentially be a subgroup of those with “pre IIH”
as post CSF removal, 7 out of the 9 had improvement of
symptoms.
In addition, we suggest that funduscopic evaluation is
sufficient and mandatory to exclude papilledema in refractory
CH patients, considering that none of our patients with negative
funduscopic exam had OCT sign of papilledema. As a corollary,
in contrast to a previous report in chronic migraine patients, all
our refractory patients had RNFL thickness within normal range,
supporting the hypothesis that long duration of headache does
not affect the eye (24).
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FIGURE 1 | Patient that fulfilled Friedman’s criteria: abnormally enlarged sella turcica that appeared partially empty (A), Enlargement of perioptic subarachnoid spaces
with faint flattening of the posterior aspect of the globe, on the left side (B), bilateral dural sinus stenosis, at the distal portion of the transverse segment (C,D).
TABLE 5 | Flow chart of patients included in the study and results.
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TABLE 6 | Summary of previous studies performing CSF pressure measurement in headache patients.
Author
(Year)
Headache patients that
underwent LP (n)
Diagnosis of headache Method of CSF
pressure measurement
CSF pressure >200 mmH2O CSF pressure >250 mmH2O
(14) 85 refractory CM single LP, 20G needle 12/85 (14.1%) 11/85 (12.9%)
(13) 10 refractory CM, NDPH, CTTH CSF monitoring, 14G
needle
9/9 (100%) 5/9 (55.5%)
(15) 28 Migraine single LP, 20G needle 19/28 (67.8%) NA
(16) 60 CM single LP, 22G needle 6/60 (10%) 3/60 (5%)
(17) 13 CTTH single LP, 20G needle 9/13 (69.2%) 6/13 (46.1%)
(12) 48 CM, CTTH 1h-CSF monitoring,
20-22G needle
18/48 (37.5%) NA
(9) 44 refractory CM single LP, 20G needle 38/44 (86.4%) 19/44 (43.2%)
CM, chronic migraine; CTTH, chronic tension type headache; LP, lumbar puncture; NDPH, New Daily Persistent Headache.
The study was limited by the relatively small sample size
to compare patients with OP > 250 mmH2O with those with
OP > 200 mmH2O and to evaluate the effect of CSF withdrawal.
However, for feasibility reasons we did not recruit further
patients. Moreover the effect of CSF withdrawal should be
investigated by mean of a randomized control study. We think
that a future multicenter study with a larger number of refractory
CH patients is necessary in order to reach meaningful results
and better define the characteristics of patients with OP > 250
mmH2O.
CONCLUSION
IIHWOP is a rare clinical condition that should be considered
in patients with chronic headache refractory to medical
treatment. Our results confirm that the combination of
neuroradiological findings (transverse sinus stenosis, empty
sella, flattening of the posterior aspect of the globe and
distention of the perioptic subarachnoid space) support the
presence of increased intracranial pressure. Determination
of CSF opening pressure remains mandatory when brain
RM finding suggest pseudotumor cerebri and may result in
headache improvement. We agree with Friedman’s diagnostic
criteria that a diagnosis of IIHWOP should be based on
the CSF OP and the combination of neuroradiological
findings.
However, based on our results, where to set the CSF OP upper
limit in IIHWOP, which may be a milder form of pseudotumor
cerebri, remains an open question. We suggest that diagnostic
criteria should be tested in other studies in different centers in
order to validate or revise it.
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